DongKookPharmaceuticalCo.,Ltd. Logo

DongKookPharmaceuticalCo.,Ltd.

Develops, manufactures, and distributes pharmaceuticals and healthcare products globally.

086450 | KO

Overview

Corporate Details

ISIN(s):
KR7086450004
LEI:
Country:
South Korea
Address:
서울특별시 강남구 영동대로 715 동국제약 청담빌딩, 강남구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Established in 1968, Dongkook Pharmaceutical Co., Ltd. is a company engaged in the research, development, manufacture, and distribution of pharmaceuticals, medical devices, and healthcare products. With a core philosophy centered on improving human life, the company focuses on human-oriented R&D and operates its own Active Pharmaceutical Ingredient (API) synthesis facilities. Its diverse portfolio includes prescription and non-prescription drugs, generic medications, and specialized therapeutic products such as anesthetics, contrast media, and anti-cancer agents. The company also produces well-known consumer brands like Madecassol and Oramedy, serving both domestic and international markets.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 5.9 MB
2025-08-12 00:00
Earnings Release
연결재무제표기준영업(잠정)실적(공정공시)
Korean 16.3 KB
2025-07-10 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 413.5 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 3.0 MB
2025-03-21 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 21.0 KB
2025-03-13 00:00
Audit Report / Information
감사보고서제출
Korean 24.6 KB
2025-03-13 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 666.2 KB
2025-03-06 00:00
Pre-Annual General Meeting Information
주주총회집중일개최사유신고
Korean 4.1 KB
2025-03-06 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 187.3 KB
2025-02-13 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 9.9 KB
2025-02-06 00:00
Notice of Dividend Amount
현금ㆍ현물배당결정
Korean 11.2 KB
2024-12-13 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.3 KB
2024-12-13 00:00
Notice of Dividend Amount
현금ㆍ현물배당을위한주주명부폐쇄(기준일)결정
Korean 5.7 KB
2024-11-14 00:00
Quarterly Report
분기보고서 (2024.09)
Korean 1.6 MB
2024-10-15 00:00
M&A Activity
타법인주식및출자증권취득결정
Korean 33.7 KB

Automate Your Workflow. Get a real-time feed of all DongKookPharmaceuticalCo.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for DongKookPharmaceuticalCo.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for DongKookPharmaceuticalCo.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

SOLIGENIX, INC. Logo
Late-stage biopharma developing treatments for rare diseases and public health threats.
United States of America
SNGX
Sonnet BioTherapeutics Holdings, Inc. Logo
Develops targeted cytokine therapies for cancer using a proprietary albumin-binding platform.
United States of America
SONN
Sonoma Pharmaceuticals, Inc. Logo
Develops and sells stabilized HOCl products for wound, skin, eye, nasal, and animal healthcare.
United States of America
SNOA
Sopharma AD Logo
Develops, manufactures, and distributes pharmaceuticals and generics in Bulgaria and regional markets.
Bulgaria
SFA
Spago Nanomedical AB Logo
Developing nanomedicines for precise cancer diagnosis and targeted radionuclide therapy.
Sweden
SPAGO
Spero Therapeutics, Inc. Logo
Develops novel treatments for multi-drug resistant bacterial infections and rare diseases.
United States of America
SPRO
Spexis AG Logo
Clinical-stage biopharma developing macrocyclic therapeutics for rare diseases and oncology.
Switzerland
SPEX
Sprint Bioscience Logo
Develops & out-licenses preclinical oncology drugs for difficult-to-treat cancers.
Sweden
SPRINT
SPRUCE BIOSCIENCES, INC. Logo
Developing first-in-class therapies for serious, underserved neurological conditions like MPS IIIB.
United States of America
SPRB
Spyre Therapeutics, Inc. Logo
Engineering advanced antibody therapies for IBD and other immune diseases.
United States of America
SYRE

Talk to a Data Expert

Have a question? We'll get back to you promptly.